A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback